facebook button Exelixis: Cabozantinib plus Atezolizumab for Subjects with Locally Advanced or Metastatic Solid Tumors
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Exelixis: Cabozantinib plus Atezolizumab for Subjects with Locally Advanced or Metastatic Solid Tumors

Sponsor: Exelixis

Protocol XL184-021: A phase 1 trial of combination therapy comprised of cabozantinib and atezolizumab in patients with advanced or metastatic solid tumors.
The trial is available to patients diagnosed with the following tumor types:

Non-small Cell Lung Cancer (Non-squamous)
Castration-Resistant Prostate Cancer (High Risk, Adenocarcinoma).

For more information please contact the clinical research department: 631-675-5075